Targeted Genetics Corp /WA/ - Current report filing (8-K)
06 6월 2008 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
___________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported)
|
May
30, 2008
|
Targeted
Genetics Corporation
|
(Exact
name of registrant as specified in its
charter)
|
Washington
|
0-23930
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
98101
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code
|
(206)
623-7612
|
Not
Applicable
|
(Former
name or former address if changed since last
report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
On
May
30, 2008,
Targeted
Genetics reported additional data from its inflammatory arthritis clinical
trial.
Copies
of
the press release and clarifying statement related to this announcement are
attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated into this current
report by reference.
Item
9.01. Financial Statements and
Exhibits.
Exhibits.
99.1
|
Press
Release of Targeted Genetics Corporation dated May 30,
2008
|
99.2
|
Clarifying
Statement of Targeted Genetics Corporation dated May 30,
2008
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
Targeted
Genetics Corporation
|
|
|
|
Dated:
June 5, 2008
|
By:
|
/s/
David J. Poston
|
|
David
J. Poston
|
|
Vice
President Finance and
Chief
Financial Officer
|
INDEX
TO EXHIBITS
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release of Targeted Genetics Corporation dated May 30,
2008
|
99.2
|
Clarifying
Statement of Targeted Genetics Corporation dated May 30,
2008
|
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024